Vivos Therapeutics (VVOS) Competitors $3.19 -0.01 (-0.31%) Closing price 04:00 PM EasternExtended Trading$3.22 +0.04 (+1.10%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VVOS vs. NSPR, SRTS, NTRB, MLSS, VANI, GUTS, ICAD, CTSO, MBOT, and APTShould you be buying Vivos Therapeutics stock or one of its competitors? The main competitors of Vivos Therapeutics include InspireMD (NSPR), Sensus Healthcare (SRTS), Nutriband (NTRB), Milestone Scientific (MLSS), Vivani Medical (VANI), Fractyl Health (GUTS), iCAD (ICAD), Cytosorbents (CTSO), Microbot Medical (MBOT), and Alpha Pro Tech (APT). These companies are all part of the "medical equipment" industry. Vivos Therapeutics vs. InspireMD Sensus Healthcare Nutriband Milestone Scientific Vivani Medical Fractyl Health iCAD Cytosorbents Microbot Medical Alpha Pro Tech InspireMD (NYSE:NSPR) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, community ranking, risk, institutional ownership, earnings, analyst recommendations and media sentiment. Do insiders & institutionals have more ownership in NSPR or VVOS? 44.8% of InspireMD shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 29.7% of InspireMD shares are owned by company insiders. Comparatively, 3.0% of Vivos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, NSPR or VVOS? InspireMD has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.47, indicating that its share price is 647% more volatile than the S&P 500. Is NSPR or VVOS more profitable? Vivos Therapeutics has a net margin of -86.19% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat Vivos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets InspireMD-413.96% -69.42% -57.68% Vivos Therapeutics -86.19%-335.04%-93.58% Which has higher earnings and valuation, NSPR or VVOS? Vivos Therapeutics has higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInspireMD$7.01M11.40-$19.92M-$0.78-3.45Vivos Therapeutics$14.58M1.24-$13.58M-$5.68-0.54 Do analysts prefer NSPR or VVOS? InspireMD currently has a consensus target price of $4.75, suggesting a potential upside of 76.51%. Vivos Therapeutics has a consensus target price of $6.30, suggesting a potential upside of 105.55%. Given Vivos Therapeutics' higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than InspireMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InspireMD 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Vivos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in NSPR or VVOS? Vivos Therapeutics received 11 more outperform votes than InspireMD when rated by MarketBeat users. Likewise, 57.69% of users gave Vivos Therapeutics an outperform vote while only 4.21% of users gave InspireMD an outperform vote. CompanyUnderperformOutperformInspireMDOutperform Votes44.21%Underperform Votes9195.79% Vivos TherapeuticsOutperform Votes1557.69% Underperform Votes1142.31% Does the media prefer NSPR or VVOS? In the previous week, InspireMD and InspireMD both had 3 articles in the media. Vivos Therapeutics' average media sentiment score of 0.47 beat InspireMD's score of 0.20 indicating that Vivos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InspireMD 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vivos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryVivos Therapeutics beats InspireMD on 9 of the 15 factors compared between the two stocks. Remove Ads Get Vivos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VVOS vs. The Competition Export to ExcelMetricVivos TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.29M$4.41B$5.63B$8.10BDividend YieldN/A32.64%4.56%4.02%P/E Ratio-0.5528.9324.5519.02Price / Sales1.2449.04383.6492.49Price / CashN/A51.0838.1634.64Price / Book13.936.126.954.34Net Income-$13.58M$67.64M$3.20B$247.23M7 Day Performance-12.68%-1.98%-2.42%-0.71%1 Month Performance-9.59%-0.40%2.96%-3.92%1 Year Performance-32.79%14.94%11.14%1.61% Vivos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VVOSVivos Therapeutics2.571 of 5 stars$3.19-0.3%$6.30+97.5%-28.4%$18.79M$14.58M-0.56160Short Interest ↓NSPRInspireMD2.4842 of 5 stars$2.80flat$4.75+69.6%+16.5%$83.13M$7.01M-3.7350Analyst ForecastNews CoverageGap UpSRTSSensus Healthcare2.3837 of 5 stars$4.86+4.5%$13.00+167.5%+16.3%$80.17M$41.81M12.1540NTRBNutriband3.3005 of 5 stars$6.57+6.0%$13.00+97.9%+120.3%$72.97M$2.02M-9.2510Short Interest ↓Positive NewsMLSSMilestone Scientific1.0183 of 5 stars$0.91-1.7%$1.25+37.4%+61.1%$70.88M$8.88M-13.0030VANIVivani Medical2.9969 of 5 stars$1.10+0.9%$4.00+263.6%-40.4%$65.16MN/A-2.4420Analyst ForecastNews CoverageGUTSFractyl Health2.1847 of 5 stars$1.27-0.8%$10.00+687.4%-83.5%$62.13M$93,000.00-0.10102Positive NewsICADiCAD0.5622 of 5 stars$2.33+1.7%N/A+39.7%$61.84M$18.94M-17.92140Analyst UpgradePositive NewsCTSOCytosorbents2.1486 of 5 stars$1.13+2.7%$4.67+313.0%+14.6%$61.79M$33.79M-3.14220Upcoming EarningsAnalyst ForecastGap UpMBOTMicrobot Medical1.6514 of 5 stars$1.66+7.8%$9.00+442.2%+35.1%$57.68MN/A-2.0720Earnings ReportNews CoverageAPTAlpha Pro TechN/A$5.11-0.8%N/A-22.7%$55.56M$59.29M13.81120High Trading Volume Remove Ads Related Companies and Tools Related Companies InspireMD Competitors Sensus Healthcare Competitors Nutriband Competitors Milestone Scientific Competitors Vivani Medical Competitors Fractyl Health Competitors iCAD Competitors Cytosorbents Competitors Microbot Medical Competitors Alpha Pro Tech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VVOS) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VVOS Stock Free VVOS Stock Alerts